미국의 에어로졸 약물전달 기기 시장 : 시장 규모, 점유율, 동향 분석 보고서 - 유형별, 용도별, 유통 채널별, 부문 예측(2025-2030년)

Market Size & Trends:

The U.S. aerosol drug delivery devices market size was estimated at USD 11.27 billion in 2024 and is expected to grow at a CAGR of 15.1% from 2025 to 2030. This is attributed to the rising prevalence of respiratory diseases, advancements in inhaler technology, increasing healthcare awareness, and the growing demand for home-based treatments. According to estimates from the American Lung Association, in 2022, approximately 11.7 million people, or 4.6% of adults, were diagnosed with COPD, including chronic bronchitis and emphysema.

In addition, the WHO projects that by 2030, life-threatening respiratory diseases such as COPD, lung cancer, and tuberculosis will be responsible for nearly one in five deaths worldwide. Such factors contribute to the widespread adoption of aerosol devices, including inhalers and nebulizers. The growing emphasis on home healthcare contributes to the increased adoption of aerosol drug delivery devices.

Patients and healthcare providers are seeking treatments administered in the comfort of home, reducing the need for hospital visits and associated healthcare costs. This shift drives demand for portable, user-friendly aerosol delivery devices that facilitate self-management of respiratory conditions. The availability of e-commerce platforms and online pharmacies has further enhanced accessibility to these devices.

Technological advancements in aerosol drug delivery devices significantly propel market growth. Smart inhalers with sensors to monitor medication usage and improve adherence are becoming increasingly prevalent. Innovations include dual-chamber DPIs, breath-actuated MDIs, and environmentally friendly propellants. These technologies enhance drug delivery efficiency and patient convenience. For instance, Aerogen's vibrating mesh nebulizer technology, now widely adopted in U.S. hospitals, exemplifies innovation in improving treatment for ventilated and non-ventilated patients. Such advancements make devices more straightforward and practical, encouraging patient and healthcare provider adoption.

The COVID-19 pandemic had a positive impact on the U.S. market. The demand for inhalers and nebulizers surged as COVID-19 and related respiratory conditions increased, particularly affecting patients with asthma and COPD who required ongoing respiratory care. The shift toward at-home healthcare and telemedicine drove the adoption of portable and smart inhalation devices. However, the pandemic disrupted supply chains, leading to raw material shortages and production delays, temporarily constraining market growth. In addition, hospitals prioritized critical COVID-19 care, causing a decline in non-urgent respiratory treatments and procedures. Despite these setbacks, the crisis accelerated digital health innovation and supported the long-term outlook of the U.S. market.

U.S. Aerosol Drug Delivery Devices Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. aerosol drug delivery devices market report based on type, application, and distribution channel:

• Type Outlook (Revenue, USD Million, 2018 - 2030)
• Inhaler
  • Pressurized Metered-Dose Inhaler (pMDI)
  • Dry-Powder Inhaler (DPI)
• Nebulizer
  • Jet
  • Mesh
  • Active
  • Passive
  • Ultrasonic
• Application Outlook (Revenue, USD Million, 2018 - 2030)
• COPD
• Asthma
• Cystic Fibrosis
• Other (Pulmonary Arterial Hypertension (PAH), etc.)
• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
• Retail Pharmacies
• Online Pharmacies
• Institutional Pharmacies

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Segment Definitions
• 1.2. Estimates and Forecast Timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
  • 1.4.5. Details of Primary Research
  • 1.4.6. Research Assumption
• 1.5. Information or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Data Visualization
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
• 1.8. Objectives
  • 1.8.1. Objective - 1
  • 1.8.2. Objective - 2
  • 1.8.3. Objective - 3
• 1.9. List of Secondary Sources
• 1.10. List of Secondary Sources

Chapter 2. Executive Summary

• 2.1. U.S. Aerosol Drug Delivery Devices Market
  • 2.1.1. Market Snapshot
  • 2.1.2. Segment Snapshot
    • 2.1.2.1. Type segment outlook
    • 2.1.2.2. Application segment outlook
    • 2.1.2.3. Distribution channel segment outlook
  • 2.1.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Currently Available Aerosol Drug Formulations and Cost Analysis
• 3.4. Pricing Analysis
• 3.5. Market Dynamics
  • 3.5.1. Market Driver Analysis
    • 3.5.1.1. Rising prevalence of respiratory diseases
    • 3.5.1.2. Technological advancements
    • 3.5.1.3. Rising geriatric population
    • 3.5.1.4. Increasing awareness of self-medication and home healthcare
  • 3.5.2. Market Restraint Analysis
    • 3.5.2.1. High cost of devices
  • 3.5.3. Market Opportunity Analysis
  • 3.5.4. Market Challenges Analysis
• 3.6. U.S. Aerosol Drug Delivery Devices Market Analysis Tools: PESTEL
  • 3.6.1. Political & Legal
  • 3.6.2. Economic & Social
  • 3.6.3. Technology
• 3.7. U.S. Aerosol Drug Delivery Devices Market Analysis Tools: Porter's

Chapter 4. U.S. Aerosol Drug Delivery Devices Market: Type Estimates & Trend Analysis

• 4.1. U.S. Aerosol Drug Delivery Devices Market: Type Movement Analysis
• 4.2. U.S. Aerosol Drug Delivery Devices Market: Type Segment Dashboard
• 4.3. Type Movement & Market Share Analysis, 2024 & 2030
• 4.4. U.S. Aerosol Drug Delivery Devices Market Estimates & Forecast, by Type
• 4.5. Inhaler
  • 4.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 4.5.2. Pressurized Metered-Dose Inhaler (pMDI)
    • 4.5.2.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 4.5.3. Dry-Powder Inhaler (DPI)
    • 4.5.3.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
• 4.6. Nebulizer
  • 4.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 4.6.2. Jet
    • 4.6.2.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 4.6.3. Mesh
    • 4.6.3.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
    • 4.6.3.2. Active
      • 4.6.3.2.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
    • 4.6.3.3. Passive
      • 4.6.3.3.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 4.6.4. Ultrasonic
    • 4.6.4.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)

Chapter 5. U.S. Aerosol Drug Delivery Devices Market: Application Estimates & Trend Analysis

• 5.1. U.S. Aerosol Drug Delivery Devices Market: Application Movement Analysis
• 5.2. U.S. Aerosol Drug Delivery Devices Market: Application Segment Dashboard
• 5.3. Application Movement & Market Share Analysis, 2024 & 2030
• 5.4. U.S. Aerosol Drug Delivery Devices Market Estimates & Forecast, by Application
• 5.5. COPD
  • 5.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
• 5.6. Asthma
  • 5.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
• 5.7. Cystic Fibrosis
  • 5.7.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
• 5.8. Other (Pulmonary Arterial Hypertension (PAH), etc.)
  • 5.8.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)

Chapter 6. U.S. Aerosol Drug Delivery Devices Market: Distribution Channel Estimates & Trend Analysis

• 6.1. U.S. Aerosol Drug Delivery Devices Market: Distribution Channel Movement Analysis
• 6.2. U.S. Aerosol Drug Delivery Devices Market: Distribution Channel Segment Dashboard
• 6.3. Distribution Channel Movement & Market Share Analysis, 2024 & 2030
• 6.4. U.S. Aerosol Drug Delivery Devices Market Estimates & Forecast, by Distribution Channel
• 6.5. Retail Pharmacies
  • 6.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
• 6.6. Online Pharmacies
  • 6.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
• 6.7. Institutional Pharmacies
  • 6.7.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company Categorization
• 7.2. Company Market Position/Share Analysis, 2024
• 7.3. Company Share Analysis
• 7.4. Company Profiles/Listing
  • 7.4.1. AptarGroup, Inc.
    • 7.4.1.1. Participant's Overview
    • 7.4.1.2. Financial Performance
    • 7.4.1.3. Product Benchmarking
    • 7.4.1.4. Recent Developments
  • 7.4.2. Koninklijke Philips N.V.
    • 7.4.2.1. Participant's Overview
    • 7.4.2.2. Financial Performance
    • 7.4.2.3. Product Benchmarking
    • 7.4.2.4. Recent Developments
  • 7.4.3. AstraZeneca
    • 7.4.3.1. Participant's Overview
    • 7.4.3.2. Financial Performance
    • 7.4.3.3. Product Benchmarking
    • 7.4.3.4. Recent Developments
  • 7.4.4. Novartis AG
    • 7.4.4.1. Participant's Overview
    • 7.4.4.2. Financial Performance
    • 7.4.4.3. Product Benchmarking
    • 7.4.4.4. Recent Developments
  • 7.4.5. Sanofi
    • 7.4.5.1. Participant's Overview
    • 7.4.5.2. Financial Performance
    • 7.4.5.3. Product Benchmarking
    • 7.4.5.4. Recent Developments
  • 7.4.6. OMRON Corporation
    • 7.4.6.1. Participant's Overview
    • 7.4.6.2. Financial Performance
    • 7.4.6.3. Product Benchmarking
    • 7.4.6.4. Recent Developments
  • 7.4.7. Medline Industries, LP.
    • 7.4.7.1. Participant's Overview
    • 7.4.7.2. Financial Performance
    • 7.4.7.3. Product Benchmarking
    • 7.4.7.4. Recent Developments
  • 7.4.8. GF Health Products, Inc.
    • 7.4.8.1. Participant's Overview
    • 7.4.8.2. Financial Performance
    • 7.4.8.3. Product Benchmarking
    • 7.4.8.4. Recent Developments
  • 7.4.9. DRIVE MEDICAL GMBH & CO. KG
    • 7.4.9.1. Participant's Overview
    • 7.4.9.2. Financial Performance
    • 7.4.9.3. Product Benchmarking
    • 7.4.9.4. Recent Developments
  • 7.4.10. Teva Pharmaceutical Industries Ltd.
    • 7.4.10.1. Participant's Overview
    • 7.4.10.2. Financial Performance
    • 7.4.10.3. Product Benchmarking
    • 7.4.10.4. Recent Developments
  • 7.4.11. Aerogen (Stamford Devices Limited Group)
    • 7.4.11.1. Participant's Overview
    • 7.4.11.2. Financial Performance
    • 7.4.11.3. Product Benchmarking
    • 7.4.11.4. Recent Developments
  • 7.4.12. Sensirion AG
    • 7.4.12.1. Participant's Overview
    • 7.4.12.2. Financial Performance
    • 7.4.12.3. Product Benchmarking
    • 7.4.12.4. Recent Developments
  • 7.4.13. PARI Respiratory Equipment, Inc.
    • 7.4.13.1. Participant's Overview
    • 7.4.13.2. Financial Performance
    • 7.4.13.3. Product Benchmarking
    • 7.4.13.4. Recent Developments
  • 7.4.14. Catalent, Inc.
    • 7.4.14.1. Participant's Overview
    • 7.4.14.2. Financial Performance
    • 7.4.14.3. Product Benchmarking
    • 7.4.14.4. Recent Developments
  • 7.4.15. Pfizer Inc.
    • 7.4.15.1. Participant's Overview
    • 7.4.15.2. Financial Performance
    • 7.4.15.3. Product Benchmarking
    • 7.4.15.4. Recent Developments
  • 7.4.16. Beurer GmbH
    • 7.4.16.1. Participant's Overview
    • 7.4.16.2. Financial Performance
    • 7.4.16.3. Product Benchmarking
    • 7.4.16.4. Recent Developments